Abstract
This article (Clinical Medicine Insights: Oncology. 2012;6:407-21. doi: 10.4137/CMO.S7340) is corrected at the request of the original authors. Table 2 contains an error.
The table compares gefitinib to placebo in the INTEREST trial. In this trial, gefitinib was compared to Docetaxel and not placebo.